Format

Send to

Choose Destination
J Proteome Res. 2004 Mar-Apr;3(2):209-17.

Clinical proteomics: revolutionizing disease detection and patient tailoring therapy.

Author information

1
NCI/FDA Clinical Proteomics Program, Office of Cell and Gene Therapy, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. petricoin@cber.fda.gov

Abstract

The evolving discipline of Clinical Proteomics is more than simply describing and enumerating the systematic changes in the protein constituency of a cell, or just generating lists of proteins that increase or decrease in expression as a cause or consequence of disease. Clinical applications of proteomics involve the use of proteomic technologies at the bedside with the ultimate goal to characterize the information flow through the intra- and extracellular molecular protein networks that interconnect organ and circulatory systems together. These networks are both new targets for therapeutics themselves as well as underpin the dynamic changes that give rise to cascades of new diagnostic biomarkers. The analysis of human cancer can be used as a model for how clinical proteomics is having an impact at the bedside for early detection, rational therapeutic targeting, and patient-tailored therapy.

PMID:
15113096
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center